At the time of writing, Plus Therapeutics Inc [PSTV] stock is trading at $1.38, up 170.06%. An important factor to consider is whether the stock is rising or falling in short-term value. The PSTV shares have gain 83.98% over the last week, with a monthly amount glided 15.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Plus Therapeutics Inc [NASDAQ: PSTV] stock has seen the most recent analyst activity on March 17, 2025, when D. Boral Capital initiated its Buy rating and assigned the stock a price target of $9. Previously, Ladenburg Thalmann started tracking the stock with Buy rating on January 25, 2021, and set its price target to $8. On October 16, 2020, Maxim Group initiated with a Buy rating and assigned a price target of $6 on the stock.
For the past year, the stock price of Plus Therapeutics Inc fluctuated between $0.24 and $2.67. Plus Therapeutics Inc [NASDAQ: PSTV] shares were valued at $1.38 at the most recent close of the market.
Analyzing the PSTV fundamentals
According to Plus Therapeutics Inc [NASDAQ:PSTV], the company’s sales were 5.72M for trailing twelve months, which represents an 17.42% jump. Gross Profit Margin for this corporation currently stands at 0.26% with Operating Profit Margin at -3.43%, Pretax Profit Margin comes in at -3.02%, and Net Profit Margin reading is -3.02%. To continue investigating profitability, this company’s Return on Assets is posted at -1.85, Equity is 2.71 and Total Capital is 2.85. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.66.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. However, for the 1st resistance point, the stock is sitting at 2.1233, and for the 2nd resistance point, it is at 2.8665.
Ratios To Look Out For
It is important to note that Plus Therapeutics Inc [NASDAQ:PSTV] has a current ratio of 0.44. On the other hand, the Quick Ratio is 0.44, and the Cash Ratio is 0.1. Considering the valuation of this stock, the price to sales ratio is 2.84.
Transactions by insiders
Recent insider trading involved Hawkins Richard J, Director, that happened on Sep 13 ’24 when 4000.0 shares were purchased. Director, Hawkins Richard J completed a deal on Sep 12 ’24 to buy 6285.0 shares. Meanwhile, Director Petersen Greg bought 12500.0 shares on Sep 11 ’24.
